Last edition
News about "Upadacitinib "
MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients
The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.
Upadacitinib | 14/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members